AMIC gets exclusive rights to resorbable brachytherapy seed

10/7/2010 | Yahoo!

Advanced Medical Isotope has secured a global license for a brachytherapy seed that can be used for the treatment of prostate cancer and other tumors that are resistant to radiation therapies. AMIC plans to submit this month a 510(k) application to the FDA for the brachytherapy seed, which can regulate the delivery of yttrium-90 microspheres to cancer tissues.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY